Edition:
India

Edwards Lifesciences Corp (EW.N)

EW.N on New York Stock Exchange

117.16USD
23 Aug 2016
Change (% chg)

$0.17 (+0.15%)
Prev Close
$116.99
Open
$117.47
Day's High
$117.82
Day's Low
$116.75
Volume
223,860
Avg. Vol
360,339
52-wk High
$118.92
52-wk Low
$62.69

EW.N

Chart for EW.N

About

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company manufactures heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a... (more)

Overall

Beta: 0.61
Market Cap(Mil.): $24,904.69
Shares Outstanding(Mil.): 212.88
Dividend: --
Yield (%): --

Financials

FDA widens use of Edwards' devices for heart valve replacement

The U.S. Food and Drug Administration has widened the use of Edwards Lifesciences Corp's heart valves to patients at intermediate risk of complications if they underwent open heart surgery.

19 Aug 2016

FDA widens use of Edwards' devices for heart valve replacement

Aug 18 The U.S. Food and Drug Administration has widened the use of Edwards Lifesciences Corp's heart valves to patients at intermediate risk of complications if they underwent open heart surgery.

19 Aug 2016

BRIEF-EDWARDS INTUITY Elite Rapid Deployment Valve receives FDA approval

* Edwards INTUITY Elite Rapid Deployment Valve receives FDA approval Source text for Eikon: Further company coverage:

15 Aug 2016

BRIEF-Stantec signs letter of intent to acquire NYC-based Edwards & Zuck

* Stantec signs letter of intent to acquire NYC-based Edwards & Zuck: 120-person premiere buildings engineering firm Source text for Eikon: Further company coverage:

12 Aug 2016

BRIEF-Edwards Lifesciences gets pproval for Sapien 3 heart valve in Canada

* Edwards Lifesciences receives approval for sapien 3 heart valve in canada Source text for Eikon: Further company coverage: (Bengaluru Newsroom +91 80 6749-1130; within U.S. +1 646 223 8780)

27 Jul 2016

UPDATE 2-Edwards Lifesciences lifts forecast on heart valve sales

July 26 Edwards Lifesciences Corp on Tuesday raised its full-year earnings forecast as quarterly profits beat estimates, and said U.S. regulators would soon likely approve its minimally invasive replacement heart valve for a broader range of patients.

27 Jul 2016

BRIEF-Edwards Lifesciences Q2 Adjusted EPS $0.76

* Sees Q3 Sales Between $720 Mln - $760 Mln; Sees Q3 Adjusted Earnings Per Share Between $0.62 - $0.68

27 Jul 2016

Edwards Lifesciences lifts outlook on heart valve sales momentum

July 26 Edwards Lifesciences Corp on Tuesday boosted its full-year earnings outlook after posting a stronger-than-expected quarterly profit and said it expects to soon gain U.S. approval to offer its minimally invasive replacement heart valve to a broader range of patients.

27 Jul 2016

UPDATE 2-Edwards raises outlook, plans for valve label expansion

April 26 Edwards Lifesciences Corp on Tuesday raised its full-year sales and profit outlook following strong first-quarter results and said approval for expanded use of its minimally invasive heart valve implant could come sooner than previously expected.

27 Apr 2016

Edwards CEO says aims for early Q4 launch of valve for new patient group

April 26 EDWARDS LIFESCIENCES CEO SAYS PLANNING FOR FDA APPROVAL, LAUNCH OF TAVR FOR INTERMEDIATE-RISK PATIENTS AT BEGINNING OF Q4 EDWARDS CEO SAYS APPROVAL COULD COME SOONER DUE TO STRENGTH OF STUDY DATA, BUT HARD TO PREDICT REGULATORY TIMELINES EDWARDS CEO SAYS COMPANY ON TRACK TO SUBMIT FINAL DATA SETS FOR INTERMEDIATE-RISK PATIENTS TO FDA IN NEXT COUPLE OF WEEKS (Reporting by Susan Kelly in Chicago)

27 Apr 2016

Earnings vs. Estimates